Immix Biopharma, Inc. filings document a Nasdaq-listed clinical-stage biopharmaceutical company with common stock registered under ticker IMMX and a development program centered on NXC-201 for relapsed/refractory AL Amyloidosis. Current reports include Regulation FD and other-event disclosures for NEXICART-2 clinical updates and regulatory-development matters.
The company’s SEC record also covers capital-structure activity, including at-the-market sales agreements, shelf registration statements, registered offerings, private placements, warrants and resale registration rights. Proxy materials disclose director elections, auditor ratification, annual-meeting voting results and other governance matters.
Janus Henderson Group plc reported beneficial ownership of 4,802,002 shares of Immix Biopharma, Inc. common stock, representing 9.1% of the class as disclosed on this Schedule 13G/A. The filing states the shares are held through multiple asset managers that exercise shared voting and dispositive power on behalf of managed portfolios.
The filing notes that the managed portfolios are the record holders entitled to dividends and sale proceeds, and that only Janus Henderson Biotech Innovation Master Fund Ltd. holds more than 5% with dividend/proceeds rights. The reporting person disclaims rights to receive dividends or sale proceeds for the asset managers described.
Immix Biopharma, Inc. reported a larger net loss as it continues to invest heavily in its cell therapy pipeline. For the three months ended March 31, 2026, net loss was $10.1 million, compared with $4.5 million a year earlier, driven by higher research and development and general and administrative expenses totaling $10.8 million.
Cash, cash equivalents and short-term investments were $90.6 million as of March 31, 2026, and total stockholders’ equity was $84.4 million. The company states this liquidity should fund operating and capital needs for at least 12 months from the filing of the quarterly report while it advances NXC‑201 and other programs.
Immix Biopharma, Inc. Schedule 13G/A amendment shows Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared beneficial ownership of 1,750,200 shares of Common Stock (CUSIP 45258H106), representing 3.3% of the class as disclosed on the cover pages. The filing states the shares are held by entities subject to voting and investment discretion of Millennium Management LLC and/or other managers affiliated with Millennium Group Management LLC and Mr. Englander and includes a Joint Filing Agreement dated May 1, 2026.
Immix Biopharma, Inc. is asking stockholders to elect nine directors and ratify its auditor at the 2026 annual meeting. The meeting is scheduled for May 22, 2026 in Los Angeles, with a March 31, 2026 record date and 53,012,092 common shares entitled to one vote each.
The proposed slate includes CEO and Chairman Ilya Rachman, CFO and President Gabriel Morris, and seven independent or non-executive directors with scientific, financial, legal and industry backgrounds. Stockholders will also vote on ratifying Crowe LLP as independent registered public accounting firm for the year ending December 31, 2026.
The company highlights that six of nine directors are Nasdaq-independent, maintains audit, compensation, and nominating/governance committees, and uses a 2021 omnibus equity incentive plan. For 2025, CEO and CFO base salaries were $475,000 each, with cash bonuses and option grants linked to clinical, operational, and financing milestones.
Immix Biopharma announced that enrollment is complete in its BLA-enabling NEXICART-2 Phase 2 trial of CAR‑T therapy NXC‑201 for relapsed/refractory AL amyloidosis, a 40‑patient U.S. study. The company expects topline NEXICART‑2 results in Q3 2026, followed by a planned biologics license application submission and potential commercial launch.
NXC‑201 has received Breakthrough Therapy, Regenerative Medicine Advanced Therapy, and Orphan Drug designations in the U.S., and Orphan status in the EU. Immix also onboarded a commercially experienced Chief Medical Officer with prior leadership roles at Merck and Johnson & Johnson to help prepare for the anticipated regulatory filing.
Immix Biopharma, Inc. filed an amended annual report mainly to correct the date of the auditor’s report, with no changes to its previously reported 2025 financials. The clinical-stage biotech, focused on cell therapies for AL amyloidosis and immune-mediated diseases, reported a 2025 net loss of $29.4 million, wider than $21.7 million in 2024, driven by higher research and development and general and administrative expenses.
Despite continued losses, Immix ended 2025 with cash and cash equivalents of $93.9 million and short-term investments of $6.5 million, lifting total assets to $104.8 million and stockholders’ equity to $93.8 million. The company raised $107.4 million net from equity offerings and an at-the-market program, and also benefited from an $8 million CIRM grant, with about $4.6 million reimbursed by year-end. Management believes existing cash plus expected grant disbursements will fund operations for at least 12 months from the filing date, even as Immix advances its pipeline and continues to generate negative operating cash flow.
Immix Biopharma, Inc. entered into Amendment No. 1 to its At The Market Offering Agreement with Citizens JMP Securities, LLC. The amended arrangement allows Immix to sell shares of common stock from time to time in an at-the-market program with an aggregate offering price of up to $100,000,000 under its effective Form S-3 shelf registration.
Citizens JMP Securities will act as sales agent and use commercially reasonable efforts to place shares within company instructions and applicable Nasdaq and regulatory limits. Immix will pay a 3.0% commission on gross sales proceeds and reimburse specified expenses up to $50,000. The filing also includes a legal opinion from Blank Rome LLP on the validity of the shares.
Immix Biopharma, Inc. proposes to offer up to $100,000,000 of Common Stock in an at-the-market offering pursuant to an ATM Agreement with Citizens JMP Securities, LLC, as amended on March 25, 2026.
The ATM permits sales from time to time on the Nasdaq Capital Market or through other permitted methods. Citizens will receive a 3.0% commission on gross sales and will be deemed an underwriter for Securities Act purposes. Proceeds to the company will vary based on actual shares sold and market prices.
Shares outstanding were 52,964,549 as of March 20, 2026, and the prospectus illustration shows up to 63,941,497 shares outstanding after the offering assuming sale of 10,976,948 shares at $9.11 per share.
Immix Biopharma, Inc. files its annual report detailing rapid progress of lead CAR‑T candidate NXC‑201 and key financings. NXC‑201 targets relapsed/refractory AL amyloidosis, a life‑threatening disease with no FDA‑approved therapies as of March 2026, and has shown high complete response rates and organ improvements in early‑phase trials with manageable safety.
The program now holds FDA Orphan Drug, RMAT and Breakthrough Therapy designations, plus European orphan status, and is being advanced in the U.S. Phase 1b/2 NEXICART‑2 trial with a planned BLA filing after final readout. Immix strengthened its balance sheet through a December 2025 underwritten offering raising approximately $100.0 million and a September 2025 private placement raising about $9.3 million, and is supported by an $8 million CIRM grant, of which $6.2 million had been reimbursed by March 20, 2026.
The company reports an aggregate market value of non‑affiliate equity of $35.7 million as of June 30, 2025, with 52,964,549 shares of common stock outstanding as of March 20, 2026. It highlights substantial ongoing losses, significant future capital needs, clinical, regulatory and manufacturing risks, heavy dependence on third parties, and potential dilution as central risk factors.